Anti-IGF-1R monoclonal antibody
Teprotumumab
Brand names: Tepezza
Adult dose
Dose: 10 mg/kg IV first dose, then 20 mg/kg IV every 3 weeks x7 doses
Route: IV
Frequency: q3w
Clinical pearls
- Active moderate-severe thyroid eye disease
- Specialist; baseline + serial audiometry/glucose
Contraindications
- Pregnancy
- Inflammatory bowel disease (caution)
- Hypersensitivity
Side effects
- Hyperglycaemia
- Hearing impairment (may be permanent)
- IBD exacerbation
- Infusion reactions
- Muscle spasms
Interactions
- Live vaccines
Monitoring
- Glucose
- Audiometry
- IBD symptoms
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/teprotumumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016